Compare Coursera Inc (COUR) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs Mesoblast Limited — how do they compare? Coursera Inc trades at $5.28 (market cap $1.39B), while Mesoblast Limited trades at $13.8 (market cap $1.75B). The key difference: Mesoblast Limited is the larger of the two by market cap, and Mesoblast Limited is more actively traded (239,027 versus 9,728,980). Which is the better fit depends on your goals — on Pluang, investors hold Coursera Inc for 47 Days and Mesoblast Limited for 14 Days on average.
| COUR | MESO | |
|---|---|---|
Market Cap | $1.39B | $1.75B |
Volume | 9,728,980 | 239,027 |
Sector | Consumer Staples | Health |
52-Week High | $10.73 | $20.96 |
52-Week Low | $4.64 | $13.19 |
Typical Hold Time | 47 Days | 14 Days |
Enterprise Value | $648.49M | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coursera (COUR) trades at $5.11, down 0.2% on the day, with a bearish technical signal and neutral oscillators. Revenue has grown from $524M in 2022 to $757.5M in 2025, but the company remains unprofitable with a net loss of $51M in 2025. Recent news highlights AI platform developments and significant institutional buying interest.
The stock offers potential upside to the $7.40 analyst consensus target but faces risks from persistent losses and competitive pressures. Positive cash flow and subscriber growth are key strengths, yet profitability challenges and integration costs from recent acquisitions present headwinds for near-term performance.
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
